Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies

Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies

Abstract Introduction Psoriasis is a chronic immune-mediated disease with significant systemic implications. Tildrakizumab, an IL-23p19 inhibitor, has demonstrated efficacy in moderate-to-severe plaque psoriasis. Higher doses may be beneficial for patients with elevated body weight or greater diseas...

Full description

Saved in:
Bibliographic Details
Main Authors: Emanuele Trovato, Tommaso Bianchelli, Giulia Odorici, Aldo Cuccia, Vito Giuseppe Di Lernia, Claudia Lasagni, Marco Manfredini, Massimiliano Nicolini, Giulia Rech, Francesca Satolli, Alessandra Cartocci, Federico Bardazzi, Anna Campanati
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-05-01
Series:Dermatology and Therapy
Subjects:
Psoriasis
Biologics
Tildrakizumab
Body mass index
Pasi
Weight
Online Access:https://doi.org/10.1007/s13555-025-01442-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01442-x

Similar Items